93 unknown. 93 Phase 3, 18 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 93 | Unknown 93 |
| Phase 2 | 18 | Unknown 18 |
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Endoscopic Visibility of Stomach After a Combination Drink of N-acetylcysteine and Simethicone Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone - Gastric Disease | Phase 3 | Unknown | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 200 | 2023-04-01 | 2023-04-06 |
| Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases Tislelizumab in Combination with Oxaliplatin and Tegafur - Liver Metastases | Phase 2 / Phase 3 | Unknown | Zhejiang University | 40 | 2022-04-10 | 2023-02-01 |
| Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis Sintilimab, Albumin-Paclitaxel, Capecitabine - Gastric Cancer | Phase 2 / Phase 3 | Unknown | Ruijin Hospital | 60 | 2021-08-07 | 2021-08-24 |
| A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression RC48-ADC, Paclitaxel injection, Irinotecan Hydrochloride Injection - Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | Phase 3 | Unknown | RemeGen Co., Ltd. | 351 | 2021-03-24 | 2023-12-21 |
| Pronase Granules in Gastric Cleaning Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8 - Gastric Disease, Capsule Endoscopy | Phase 2 / Phase 3 | Unknown | Changhai Hospital | 290 | 2021-02-24 | 2022-02-22 |
| IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy Indocyanine Green - Gastric Cancer, Lymph Node Metastases | Phase 3 | Unknown | Fujian Medical University | 240 | 2020-11-16 | 2023-09-18 |
| Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer Irinotecan, Oxaliplatin, 5-fluorouracil - Metastatic Gastric Cancer | Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 388 | 2020-10-22 | 2021-07-19 |
| Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis Catumaxomab, The treatment of investigator choice - Stomach Neoplasms | Phase 3 | Unknown | LintonPharm Co.,Ltd. | 282 | 2020-10-06 | 2023-01-31 |
| HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer Irinotecan Hydrochloride Injection, HX008, Placebo - Stomach Cancer | Phase 3 | Unknown | Taizhou Hanzhong biomedical co. LTD | 560 | 2020-09-16 | 2021-01-28 |
| Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma Docetaxel, Oxaliplatin - Gastric Cancer | Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 440 | 2020-09-15 | 2021-06-01 |
| A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer docetaxel plus oxaliplatin and capecitabine, oxaliplatin plus capecitabine - Stomach Neoplasms | Phase 3 | Unknown | LiNing | 196 | 2020-09-01 | 2020-07-16 |
| Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer nab paclitaxel, Tegafur, Oxaliplatin - Stomach Cancer | Phase 3 | Unknown | Zhejiang Cancer Hospital | 616 | 2020-03-01 | 2020-03-23 |
| Randomized Controlled Trial on Effect of Lymph Node Mapping by Indocyanine Green Via Submucosal or Subserosal Injection Subserosa injection of indocyanine green, submucosal injection of indocyanine green - Indocyanine Green, Gastric Cancer | Phase 3 | Unknown | Fujian Medical University | 266 | 2019-12-31 | 2023-10-10 |
| A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer HLX10, Placebos - Gastric Cancer | Phase 3 | Unknown | Shanghai Henlius Biotech | 642 | 2019-12-12 | 2022-06-06 |
| Oral Nutritional Supplements Compared With Standard Diet in Postoperative Gastric Cancer Patients With Adjuvant Chemotherapy NutrenOpimum - Gastric Cancer | Phase 3 | Unknown | Sun Yat-sen University | 374 | 2019-04-16 | 2019-04-17 |
| The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer Apatinib, Capecitabine - Stomach Neoplasms, Gastrointestinal Neoplasms | Phase 3 | Unknown | Fudan University | 242 | 2019-03-22 | 2019-03-26 |
| Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1 - Gastric Cancer | Phase 3 | Unknown | Huazhong University of Science and Technology | 294 | 2019-03-08 | 2022-01-04 |
| A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer POF, CAPOX/SOX/FOLFOX - Gastric Cancer Stage III | Phase 3 | Unknown | Fujian Cancer Hospital | 600 | 2019-02-01 | 2019-10-16 |
| FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma Irinotecan, 5-FU, Leucovorin - Stomach Neoplasms, Gastrointestinal Neoplasms | Phase 2 / Phase 3 | Unknown | Blokhin's Russian Cancer Research Center | 538 | 2019-01-29 | 2021-04-13 |
| Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 Resection Capecitabine monotherapy - Gastric Cancer | Phase 3 | Unknown | The First Affiliated Hospital of Anhui Medical University | 768 | 2019-01-16 | 2020-04-20 |
Showing 20 of 93. Sign in to see all of them.
Stomach Neoplasms (82) · Diabetes Mellitus (3) · Gastritis (3) · Gastroparesis (3) · Peptic Ulcer (3) · Duodenal Ulcer (2) · Esophageal Neoplasms (2) · Gastroesophageal Reflux (2) · Gastrointestinal Neoplasms (2) · Helicobacter Infections (2) · Peritoneal Neoplasms (2) · Stomach Ulcer (2) · Colonic Neoplasms (1) · Colorectal Neoplasms (1)
Digestive System Diseases (93) · Gastrointestinal Diseases (93) · Neoplasms by Site (82) · Digestive System Neoplasms (81) · Neoplasms (81) · Gastrointestinal Neoplasms (80) · Intestinal Diseases (7) · Pathological Conditions, Signs and Symptoms (7) · Duodenal Diseases (5) · Neurologic Manifestations (5) · Nutritional and Metabolic Diseases (5) · Signs and Symptoms (5) · Endocrine System Diseases (4) · Esophageal Diseases (3)
Oxaliplatin (16) · Capecitabine (11) · apatinib (8) · S 1 (combination) (7) · Irinotecan (6) · Docetaxel (5) · Drug Therapy (5) · Clarithromycin (4) · Fluorouracil (4) · Hyperthermic Intraperitoneal Chemotherapy (4) · Paclitaxel (4) · Tegafur (4) · XELOX (4) · Amoxicillin (3) · Cisplatin (3)
Sun Yat-sen University (7) · Chinese University of Hong Kong (5) · Fudan University (3) · Huazhong University of Science and Technology (3) · Samsung Medical Center (3) · Sixth Affiliated Hospital, Sun Yat-sen University (3) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (3) · Asan Medical Center (2) · Chinese PLA General Hospital (2) · Fujian Medical University (2) · Hamamatsu University (2) · Hebei Medical University (2) · Nanfang Hospital, Southern Medical University (2) · National Cancer Center, Korea (2) · Shanghai Zhongshan Hospital (2)
China (56) · South Korea (12) · Japan (4) · Hong Kong (3) · Taiwan (3) · France (2) · Poland (2) · Russia (2) · Germany (1) · India (1) · Israel (1) · Italy (1) · Nepal (1) · Netherlands (1) · South Africa (1)
Enders K.W. Ng, MD (3) · Jian Xiao, MD (2) · Lin Chen (2) · Xianglin Yuan, MD,PhD (2) · Alexey Karachun, MD, PhD (1) · Andrey Pavlenko, MD, PhD (1) · Andrey Ryabov, MD, PhD (1) · Baorui Liu, MD, PHD (1) · Barry W. Hancock, MD (1) · Bikal Ghimire, MS (1) · Boris Pomortsev, MD (1) · Byoungyong Shim, M.D.,Ph.D (1) · Catherine Geindre (1) · Chang-Ming Huang, MD (1)
PMID 10400410, PMID 11413430, PMID 11813623, PMID 11895791, PMID 15273542, PMID 1598671, PMID 16810012, PMID 17005947, PMID 17538089, PMID 17943760, PMID 18663532, PMID 19011538, PMID 19036078, PMID 19638912, PMID 19690058, PMID 19770617, PMID 20160637, PMID 20554319, PMID 21810227, PMID 22012809, PMID 23396494, PMID 25012265, PMID 25614467, PMID 26352529, PMID 26439700, PMID 26903580, PMID 27211503, PMID 27650694, PMID 27927660, PMID 28338153, PMID 28437000, PMID 29110963, PMID 29380729, PMID 29650363, PMID 30027281, PMID 30126861, PMID 30380145, PMID 30730546, PMID 30922323, PMID 31135850, PMID 31194028, PMID 31468267, PMID 31630485, PMID 32208351, PMID 32735752, PMID 32773628, PMID 33227408, PMID 33417481, PMID 33435909, PMID 34622445